Cargando…

Targeting Natural Killer T Cells in Solid Malignancies

Natural killer T (NKT) cells are a unique subset of lymphocytes that recognize lipid antigens in the context of the non-classical class I MHC molecule, CD1d, and serve as a link between the innate and adaptive immune system through their expeditious release of cytokines. Whereas NKT have well-establ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ingram, Zewde, Madan, Shriya, Merchant, Jenoy, Carter, Zakiya, Gordon, Zen, Carey, Gregory, Webb, Tonya J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227159/
https://www.ncbi.nlm.nih.gov/pubmed/34072042
http://dx.doi.org/10.3390/cells10061329
_version_ 1783712459112054784
author Ingram, Zewde
Madan, Shriya
Merchant, Jenoy
Carter, Zakiya
Gordon, Zen
Carey, Gregory
Webb, Tonya J.
author_facet Ingram, Zewde
Madan, Shriya
Merchant, Jenoy
Carter, Zakiya
Gordon, Zen
Carey, Gregory
Webb, Tonya J.
author_sort Ingram, Zewde
collection PubMed
description Natural killer T (NKT) cells are a unique subset of lymphocytes that recognize lipid antigens in the context of the non-classical class I MHC molecule, CD1d, and serve as a link between the innate and adaptive immune system through their expeditious release of cytokines. Whereas NKT have well-established roles in mitigating a number of human diseases, herein, we focus on their role in cancer. NKT cells have been shown to directly and indirectly mediate anti-tumor immunity and manipulating their effector functions can have therapeutic significances in treatment of cancer. In this review, we highlight several therapeutic strategies that have been used to harness the effector functions of NKT cells to target different types of solid tumors. We also discuss several barriers to the successful utilization of NKT cells and summarize effective strategies being developed to harness the unique strengths of this potent population of T cells. Collectively, studies investigating the therapeutic potential of NKT cells serve not only to advance our understanding of this powerful immune cell subset, but also pave the way for future treatments focused on the modulation of NKT cell responses to enhance cancer immunotherapy.
format Online
Article
Text
id pubmed-8227159
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82271592021-06-26 Targeting Natural Killer T Cells in Solid Malignancies Ingram, Zewde Madan, Shriya Merchant, Jenoy Carter, Zakiya Gordon, Zen Carey, Gregory Webb, Tonya J. Cells Review Natural killer T (NKT) cells are a unique subset of lymphocytes that recognize lipid antigens in the context of the non-classical class I MHC molecule, CD1d, and serve as a link between the innate and adaptive immune system through their expeditious release of cytokines. Whereas NKT have well-established roles in mitigating a number of human diseases, herein, we focus on their role in cancer. NKT cells have been shown to directly and indirectly mediate anti-tumor immunity and manipulating their effector functions can have therapeutic significances in treatment of cancer. In this review, we highlight several therapeutic strategies that have been used to harness the effector functions of NKT cells to target different types of solid tumors. We also discuss several barriers to the successful utilization of NKT cells and summarize effective strategies being developed to harness the unique strengths of this potent population of T cells. Collectively, studies investigating the therapeutic potential of NKT cells serve not only to advance our understanding of this powerful immune cell subset, but also pave the way for future treatments focused on the modulation of NKT cell responses to enhance cancer immunotherapy. MDPI 2021-05-27 /pmc/articles/PMC8227159/ /pubmed/34072042 http://dx.doi.org/10.3390/cells10061329 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ingram, Zewde
Madan, Shriya
Merchant, Jenoy
Carter, Zakiya
Gordon, Zen
Carey, Gregory
Webb, Tonya J.
Targeting Natural Killer T Cells in Solid Malignancies
title Targeting Natural Killer T Cells in Solid Malignancies
title_full Targeting Natural Killer T Cells in Solid Malignancies
title_fullStr Targeting Natural Killer T Cells in Solid Malignancies
title_full_unstemmed Targeting Natural Killer T Cells in Solid Malignancies
title_short Targeting Natural Killer T Cells in Solid Malignancies
title_sort targeting natural killer t cells in solid malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227159/
https://www.ncbi.nlm.nih.gov/pubmed/34072042
http://dx.doi.org/10.3390/cells10061329
work_keys_str_mv AT ingramzewde targetingnaturalkillertcellsinsolidmalignancies
AT madanshriya targetingnaturalkillertcellsinsolidmalignancies
AT merchantjenoy targetingnaturalkillertcellsinsolidmalignancies
AT carterzakiya targetingnaturalkillertcellsinsolidmalignancies
AT gordonzen targetingnaturalkillertcellsinsolidmalignancies
AT careygregory targetingnaturalkillertcellsinsolidmalignancies
AT webbtonyaj targetingnaturalkillertcellsinsolidmalignancies